Q4 Results Live Updates
Emcure Pharma Q4 & FY26: Revenue Crosses US$1 Bn; Management Targets Low- to Mid-Teen Growth in FY27
06 May 26Emcure Pharmaceuticals crossed the US$1 billion revenue milestone in FY26, with consolidated revenue growing 16.6% YoY to ₹9,204 Cr and Adj. PAT surging 40.9% to ₹1,008 Cr. International markets led growth at 22.2% YoY for FY26, while management targets low- to mid-teen revenue growth and 75-100 bps EBITDA margin expansion for FY27 under stable conditions, with international markets facing 7%-8% and Europe 11%-12% currency headwinds.
view all stories

Latest Market Updates




Today's Top Gainers





Today's Top Losers





Today's Top Gainers





Today's Top Losers





Stocks in News Today




Corporate Actions
Market Highlights
Earnings
Orders & Deals
IPO
Global News
















































